Enterin Inc. Raises $12.7 Million in Series A Financing
PHILADELPHIA, July 15, 2017 -- (Healthcare Sales & Marketing Network) -- Enterin Inc., a Philadelphia-based biotechnology company developing novel compounds to treat Parkinson's disease (PD), today announced the completion of a $12.7 million Series A fina... Biopharmaceuticals, Neurology, Venture Capital Enterin, neurodegenerative disease
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Biotechnology | Brain | Marketing | Neurology | Parkinson's Disease | Pharmaceuticals | Venture Capital